Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
102.00    0.20 (0.20%)
Bid:
102.40
Ask:
102.80
Spread: 0.40 (0.391%)
Market Cap: £167.22m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Interim Management Statement

6 May 2010 11:00

RNS Number : 4369L
Yule Catto & Co PLC
06 May 2010
Β 

ο»Ώ

6 May 2010

Β 

Yule Catto & Co plcΒ 

Β 

Interim Management Statement

Β 

Yule Catto & Co plc, the international producer of speciality chemicals, today issues its Interim Management Statement for the period from 1 January to 31 March 2010

Β 

Β 

The Group has made a good start to the year with first quarter PBT comfortably ahead of last year.

Β 

Polymer Chemicals is the Group's main business, accounting for 88% of divisional operating profit in 2009 with 50% of its revenue in Asia and emerging markets. The business made a good start to the year. Volumes were over 10% up on prior year, strongly ahead of the weak first quarter of 2009. Volumes in Asia remain strong. Whilst Europe started slowly, in part due to the difficult weather conditions, demand strengthened through the quarter and this has continued into April. Monomer prices continued to rise through the quarter and the business has continued to seek to recover these increases in the market place.

Β 

Pharma Chemicals has continued to trade weakly, with profits in the first quarter below prior year, though the business has a good current forward order book.

Β 

William Blythe, the remaining Impact Chemicals business was ahead of last year as expected.

Β 

Net debt rose during the quarter, as the improving demand position absorbed additional working capital, but is still comfortably below Β£100 million. We are still in the process of completing the announced sale of the Finewaters adhesive business, which will deliver a further reduction in debt of Β£11 million when concluded.

Β 

Looking forward in Polymers we expect to see continuing strong demand in Asia and modest volume improvement in Europe. Monomer prices have continued to rise during the second quarter and work is in hand to recover these increases. Pharma, after the slow start, is likely to trade a little below last year, whilst William Blythe will be ahead. Overall trading is in line with the Board's previous expectations for the full year.

Β 

Β 

ENQUIRIES:

Β 

YULE CATTO & Co plc

Tel: 01279 442791

Adrian Whitfield, Chief Executive

David Blackwood, Finance Director

HOGARTH

Tel: 020 7357 9477

John Olsen

Andrew Jaques

Ian Payne

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IMSLIFLTEFIRIII
Date   Source Headline
15th Nov 20054:54 pmRNSHolding(s) in Company
31st Oct 20059:45 amRNSProposed sale - Autoclenz Ltd
5th Oct 20052:36 pmRNSDirector/PDMR Shareholding
29th Sep 200512:08 pmRNSDirector/PDMR Shareholding
14th Sep 20053:02 pmRNSHolding(s) in Company
17th Aug 20059:50 amRNSNotice of Results
13th Jul 20053:46 pmRNSChief Operating Officer
1st Jul 200511:15 amRNSJames Robinson Consolidation
10th Jun 20053:12 pmRNSDirector Shareholding
10th Jun 20053:09 pmRNSDirector Shareholding
3rd Jun 20053:16 pmRNSHolding(s) in Company
3rd Jun 20053:12 pmRNSHolding(s) in Company
3rd Jun 20053:11 pmRNSHolding(s) in Company
2nd Jun 200512:41 pmRNSBlocklisting Interim Review
2nd Jun 200511:21 amRNSHolding(s) in Company
1st Jun 20054:55 pmRNSHolding(s) in Company
26th May 20054:49 pmRNSDoc re. AGM Resolutions
26th May 200512:00 pmRNSAGM Statement
23rd May 200511:41 amRNSHolding(s) in Company
21st Apr 200510:36 amRNSAnnual Report and Accounts
31st Mar 20053:41 pmRNSSale of Brencliffe Limited
23rd Mar 20053:45 pmRNSDirector Shareholding
23rd Mar 20053:44 pmRNSDirector Shareholding
4th Mar 20054:16 pmRNSDirector Shareholding
3rd Mar 20057:00 amRNSFinal Results
15th Feb 20058:51 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.